Think triple (ICS/LABA/LAMA),
think Trimbow
The only extrafine formulation ICS/LABA/LAMA
combination1,2
Designed to reach the large and small airways1,3
Trimbow pMDI 87/5/9 is indicated for the maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.1

Each dose contains three compounds for the treatment of asthma:1
- Beclometasone
- Formoterol
- Glycopyrronium
Trimbow is licensed for adult asthma patients uncontrolled on medium dose ICS/LABA who have experienced an exacerbation in the previous year1
Extrafine formulation like Fostair® (beclometasone/formoterol)1,4
Familiar pMDI device, b.d. dosing and licensed for use with an AeroChamber Plus® spacer1,5,6
Reduction in moderate and severe exacerbations vs. medium dose ICS/LABA (Fostair pMDI 100/6)1,7
For additional information to share with your patients who have been prescribed Trimbow, please visit our Trimbow patient and carer site.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.